3 Reasons DexCom Looks Like a No-Brainer Buy Right Now
DexCom (NASDAQ: DXCM) is a big name in diabetes care. Its continuous glucose monitors (CGMs) help people track their blood glucose levels.
But the stock has been performing poorly this year amid falling growth (the company projects an organic growth rate of around 11% to 13%, far lower than in the past). Investors have also been growing concerned about its prospects, especially if weight loss drugs can lead to a reduction in diabetes cases in the long run.
Down more than 40% this year, DexCom's stock has been in a tailspin. But while it might seem like a troubling time to own the stock, here are three reasons I would consider buying it.
Source Fool.com
Dexcom Inc. Aktie
64,41 €
3,09 %
Die Dexcom Inc. Aktie ist ein klarer Community-Favorit: Nur Buy-Einschätzungen, keine Sell-Einschätzungen.
Eine deutliche Steigerung um mehr als 50% ist für Dexcom Inc. mit einem Kursziel von 115 € gegenüber 64.41 € zu erwarten.
